All In Biotech

Drug Trial Radar · NCT00735397

Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Last checked: Nov 19, 2026Latest source record: Mar 14, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,218

Actual

Start

Oct 2008

Primary completion

Sep 2014

Study completion Sep 2014

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Aug 14, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the safety and tolerability of perampanel (up to 12 mg/day) given as adjunctive treatment in subjects with refractory partial seizures and to evaluate the maintenance of effect of perampanel for the control of refractory partial seizures.

Conditions

  • Epilepsy

Interventions

  • perampanelDrug

    Perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Non-Serious Adverse Events (AEs) and Treatment-emergent Serious Adverse Events (SAEs)Time frame: From date of first dose of perampanel up to 30 days after the last dose of perampanel or up to approximately 5 years.

Locations

239 sites in 39 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Phoenix, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Fresno, California

  • Site not named

    San Francisco, California

  • Site not named

    Ventura, California

  • Site not named

    Denver, Colorado

  • Site not named

    Fort Collins, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Gulf Breeze, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Tallahassee, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Suwanee, Georgia

  • Site not named

    Boise, Idaho

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Ames, Iowa

  • Site not named

    Lexington, Kentucky

  • Site not named

    Houma, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Bethesda, Maryland

  • Site not named

    Hattiesburg, Mississippi

  • Site not named

    Chesterfield, Missouri

  • Site not named

    Kansas City, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Albany, New York

  • Site not named

    Buffalo, New York

  • Site not named

    Great Neck, New York

  • Site not named

    Lawrence, New York

  • Site not named

    New York, New York

  • Site not named

    Rochester, New York

  • Site not named

    Syracuse, New York

  • Site not named

    Asheville, North Carolina

  • Site not named

    Akron, Ohio

  • Site not named

    Cincinnati, Ohio

Showing 40 of 239 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.